The Latest Cardiac and Vascular News
Case study of patient save also presented at Heart Rhythm 2023 SAN FRANCISCO–(BUSINESS WIRE)–Element Science, an innovative health technology company pioneering a digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, announced the completion of enrollment in its Jewel IDE Study (NCT05201495). A case study was also […]
HINGHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has closed its previously announced registered direct offering for the purchase and sale of 1,209,500 shares of the Company’s common stock (or common stock equivalents) at a purchase price of $2.20 per share […]
JAGUAR Study Evaluates ALTO® Compared to Other Commercially Available EVAR Devices IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company, dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced the completion of the 150th case in the JAGUAR Study. This randomized controlled trial […]
Artivion to Receive $18.75 Million Milestone Payment Under Previously Announced Agreement Artivion to Begin Supplying Product to Baxter Under Transitional Manufacturing and Supply Agreement ATLANTA, May 23, 2023 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) granted premarket […]
For the second consecutive year, Eko Health honored with Fast Company’s World Changing Ideas Awards and Inc. Magazine’s Best Workplaces OAKLAND, Calif., May 23, 2023 /PRNewswire/ — Eko Health, a leading innovator in digital health technology for heart and lung disease detection, today announced that it has been honored in Fast Company’s World Changing […]
First FGF21 analog to enter Phase 3 development SAN FRANCISCO, May 23, 2023 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the initiation of ENTRUST, a Phase 3 […]
SUNNYVALE, Calif., May 23, 2023 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announced that the next Data Safety Monitoring Board (DSMB) meeting for the CardiAMP Cell Therapy Trial for Heart Failure is scheduled to take place […]
– 44-48% Mean Reductions in LDL-C Achieved on Top of Continued Standard of Care – Phase 3 Planning is Ongoing PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3, the company’s investigational RNAi therapeutic designed to reduce expression […]
FIRST-EVER PHASE III RANDOMIZED CONTROLLED TRIAL OF ATRIAL SHUNT THERAPY SHOWS CONTINUED PROMISE TEWKSBURY, Mass., May 22, 2023 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced two-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the […]
Abbott’s AVEIR™ DR i2i™ IDE study is the industry’s first prospective study on the safety and performance of the world’s first dual-chamber leadless pacemaker The study successfully met all three of its primary safety and performance endpoints Abbott’s investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the […]
